Moderna, Inc. (MUN:0QF)
23.75
+0.50 (2.15%)
At close: Dec 9, 2025
Moderna Revenue
Moderna had revenue of $1.02B USD in the quarter ending September 30, 2025, a decrease of -45.44%. This brings the company's revenue in the last twelve months to $2.23B, down -56.07% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.07%
P/S Ratio
5.23
Revenue / Employee
$384.83K
Employees
5,800
Market Cap
9.94B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Moderna News
- 11 hours ago - XOMA Royalty Enters into Agreement to Acquire Generation Bio - Wallstreet:Online
- 15 hours ago - Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
- 15 hours ago - Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
- 20 hours ago - Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
- 21 hours ago - Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE - Finanz Nachrichten
- 21 hours ago - EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Wallstreet:Online
- 21 hours ago - EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Accesswire
- 3 days ago - ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week - Seeking Alpha